Can-Fite BioPharma (NYSE:CANF) Upgraded at StockNews.com

StockNews.com upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a sell rating to a hold rating in a report published on Tuesday.

Several other research analysts have also commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday.

Can-Fite BioPharma Trading Up 3.0 %

NYSE:CANF traded up $0.06 during midday trading on Tuesday, reaching $2.05. 2,804 shares of the stock traded hands, compared to its average volume of 67,408. The company has a fifty day moving average of $2.26 and a 200 day moving average of $2.52. Can-Fite BioPharma has a 12 month low of $1.83 and a 12 month high of $4.69.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC increased its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.